1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022; 400: 1345-62.
2. Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022; 42: 2029-41.
3. Li TY, Yang Y, Zhou G, Tu ZK. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J Gastroenterol. 2019; 25: 3527-37.
4. Yue T, Zhang Q, Cai T, Xu M, Zhu H, Pourkarim MR, et al. Trends in the disease burden of HBV and HCV infection in China from 1990-2019. Int J Infect Dis. 2022; 122: 476-85.
5. Wang H, Men P, Xiao Y, Gao P, Lv M, Yuan Q, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis. 2019; 19: 811.
6. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002; 11: 369-76.
7. Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019; 20.
8. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015; 479-480: 672-86.
9. Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022; 28: 216-29.
10. Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X, et al. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res. 2020; 26: 599-603.
11. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004; 99: 860-5.
12. Silsirivanit A. Glycosylation markers in cancer. Adv Clin Chem. 2019; 89: 189-213.
13. Kailemia MJ, Park D, Lebrilla CB. Glycans and glycoproteins as specific biomarkers for cancer. Anal Bioanal Chem. 2017; 409: 395-410.
14. Hirata T, Kizuka Y. N-Glycosylation. Adv Exp Med Biol. 2021; 1325: 3-24.
15. Huang Y, Zhang HL, Li ZL, Du T, Chen YH, Wang Y, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021; 12: 2672.
16. Miao Z, Cao Q, Liao R, Chen X, Li X, Bai L, et al. Elevated transcription and glycosylation of B3GNT5 promotes breast cancer aggressiveness. J Exp Clin Cancer Res. 2022; 41: 169.
17. Scott DA, Drake RR. Glycosylation and its implications in breast cancer. Expert Rev Proteomics. 2019; 16: 665-80.
18. Radovani B, Gudelj I. N-Glycosylation and Inflammation; the Not-So-Sweet Relation. Front Immunol. 2022; 13: 893365.
19. Tena J, Tang X, Zhou Q, Harvey D, Barajas-Mendoza M, Jin LW, et al. Glycosylation alterations in serum of Alzheimer's disease patients show widespread changes in N-glycosylation of proteins related to immune function, inflammation, and lipoprotein metabolism. Alzheimers Dement (Amst). 2022; 14: e12309.
20. Conroy LR, Hawkinson TR, Young LEA, Gentry MS, Sun RC. Emerging roles of N-linked glycosylation in brain physiology and disorders. Trends Endocrinol Metab. 2021; 32: 980-93.
21. Rudman N, Gornik O, Lauc G. Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes. FEBS Lett. 2019; 593: 1598-615.
22. Stambuk T, Gornik O. Protein Glycosylation in Diabetes. Adv Exp Med Biol. 2021; 1325: 285-305.
23. Rudman N, Kifer D, Kaur S, Simunovic V, Cvetko A, Pociot F, et al. Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG. Diabetologia. 2022; 65: 1315-27.
24. West CA, Wang M, Herrera H, Liang H, Black A, Angel PM, et al. N-Linked Glycan Branching and Fucosylation Are Increased Directly in Hcc Tissue As Determined through in Situ Glycan Imaging. J Proteome Res. 2018; 17: 3454-62.
25. Kim KJ, Kim YW, Hwang CH, Park HG, Yang YH, Koo M, et al. A MALDI-MS-based quantitative targeted glycomics (MALDI-QTaG) for total N-glycan analysis. Biotechnol Lett. 2015; 37: 2019-25.
26. Shan M, Yang D, Dou H, Zhang L. Fucosylation in cancer biology and its clinical applications. Prog Mol Biol Transl Sci. 2019; 162: 93-119.
27. Kizuka Y, Taniguchi N. Enzymes for N-Glycan Branching and Their Genetic and Nongenetic Regulation in Cancer. Biomolecules. 2016; 6.
28. Li F, Zhao S, Cui Y, Guo T, Qiang J, Xie Q, et al. α1,6-Fucosyltransferase (FUT8) regulates the cancer-promoting capacity of cancer-associated fibroblasts (CAFs) by modifying EGFR core fucosylation (CF) in non-small cell lung cancer (NSCLC). Am J Cancer Res. 2020; 10: 816-37.
29. Ma J, Sanda M, Wei R, Zhang L, Goldman R. Quantitative analysis of core fucosylation of serum proteins in liver diseases by LC-MS-MRM. J Proteomics. 2018; 189: 67-74.
30. Cao L, Zhou Y, Li X, Lin S, Tan Z, Guan F. Integrating transcriptomics, proteomics, glycomics and glycoproteomics to characterize paclitaxel resistance in breast cancer cells. J Proteomics. 2021; 243: 104266.
31. Ceroni A, Maass K, Geyer H, Geyer R, Dell A, Haslam SM. GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. J Proteome Res. 2008; 7: 1650-9.
32. Zhou J, Yang W, Hu Y, Höti N, Liu Y, Shah P, et al. Site-Specific Fucosylation Analysis Identifying Glycoproteins Associated with Aggressive Prostate Cancer Cell Lines Using Tandem Affinity Enrichments of Intact Glycopeptides Followed by Mass Spectrometry. Anal Chem. 2017; 89: 7623-30.
33. Dalal K, Dalal B, Bhatia S, Shukla A, Shankarkumar A. Analysis of serum Haptoglobin using glycoproteomics and lectin immunoassay in liver diseases in Hepatitis B virus infection. Clin Chim Acta. 2019; 495: 309-17.
34. Guo L, Wan L, Hu Y, Huang H, He B, Wen Z. Serum N-glycan profiling as a diagnostic biomarker for the identification of hepatitis B virus-associated hepatocellular carcinoma. J Gastrointest Oncol. 2022; 13: 344-54.
35. Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res. 2006; 5: 308-15.
36. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A. 2005; 102: 779-84.
37. Yao W, Wang K, Jiang Y, Huang Z, Huang Y, Yan H, et al. Serum profile of low molecular weight fucosylated glycoproteins for early diagnosis of hepatocellular carcinoma. Oncol Lett. 2020; 20: 1597-606.
38. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007; 46: 1426-35.
39. Fang M, Zhao YP, Zhou FG, Lu LG, Qi P, Wang H, et al. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Cancer. 2010; 127: 148-59.
40. Zhu J, Lin Z, Wu J, Yin H, Dai J, Feng Z, et al. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res. 2014; 13: 2986-97.
41. Yi C-H, Weng H-L, Zhou F-G, Fang M, Ji J, Cheng C, et al. Elevated core-fucosylated IgG is a new marker for hepatitis B virus-related hepatocellular carcinoma. OncoImmunology. 2015; 4: e1011503.
42. Zhang S, Cao X, Liu C, Li W, Zeng W, Li B, et al. N-glycopeptide Signatures of IgA(2) in Serum from Patients with Hepatitis B Virus-related Liver Diseases. Mol Cell Proteomics. 2019; 18: 2262-72.
43. Lux A, Nimmerjahn F. Impact of differential glycosylation on IgG activity. Adv Exp Med Biol. 2011; 780: 113-24.
44. Novak J, Barratt J, Julian BA, Renfrow MB. Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy. Semin Nephrol. 2018; 38: 461-76.
45. Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A. 2015; 112: E1297-306.
46. Maurer MA, Meyer L, Bianchi M, Turner HL, Le NPL, Steck M, et al. Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. Cell Rep. 2018; 23: 90-9.